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Abstract The aim of this work was to analyse the
characteristics of Questions and Answers (Q&As) at a drug
information centre (DIC) regarding drug related problems
and off-label drug treatment in children. All questions
concerning children 15 years or younger at a DIC in
Stockholm, Sweden during the years 1995–2004 were
analysed with respect to the main drug related problem,
drug/s and drug group/s, whether the drugs were licensed or
not, pediatric labelling of the drug/s and age and sex of the
patient. Q&As were classified as whether or not they
included evaluated literature information, adding to the
labelling of the drugs. We identified 249 Q&As concerning
pediatric drug treatment. Each question addressed an
average of 1.5 drugs. More than two-thirds of the Q&As
concerned adverse drug reactions and pediatric drug choice
or dosing. Every second question was classified as off-
label, psychotropic drugs being the most common. In half
of all off-label Q&As, pediatric documentation on drug
efficacy and safety outside the Swedish catalogue of
medical products was found. Most Q&As concerned
newborns and infants. However, the off-label proportion
among questions was highest in adolescence as well as the
evaluated literature information, adding to the labelling of
the drugs. It was thus found that off-label drug treatment is
common among pediatric questions at a DIC. This service
can provide additional literature based information contrib-
uting to a safer use of drugs in children. There is still,
however, a substantial need for clinical documentation of
drug use in children.
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Introduction
Children, and especially small children, receive consider-
able amounts of drugs [16, 21, 24, 27] and several studies
indicate that drug related problems in children are of great
clinical relevance and that many of them are preventable
[7, 12, 25].
Drug prescribing in children has been reported to
frequently be carried out in an off-label and/or unlicensed
manner, both in hospitals and in primary health care [20,
26, 27]. The term off-label in these studies is defined as the
use of a drug outside the terms of the product license for
children and unlicensed drugs are drugs that do not have a
product license.
The licensing procedure is mainly based on clinical trials
in adults and aims at ensuring the safety, efficacy and
quality of drugs. However, children differ from adults
regarding pharmacokinetics and pharmacodynamics [30].
The lack of clinical trials in children results in non-existing
pediatric labelling of many drugs and off-label pediatric
drug use. Attempts have been made by the medical
regulatory agencies to stimulate the drug industry to
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perform pediatric clinical trials [6]. However, an investiga-
tion of the license status of drugs approved after these
initiatives were implemented shows that the majority of the
drugs still lack pediatric labelling [11]. Off-label drug
treatment has been associated with an increased frequency
of ADRs compared with licensed pediatric drug treatment
[13, 28].
Since readily available information concerning pediatric
drug treatment from clinical trials and drug producers are
scarce, other sources of information, such as what might be
found at drug information centres (DICs), are needed.
The first DIC in Sweden was established in 1974,
through a co-operation of clinical pharmacologists and
information pharmacists [2]. Today, there is a regional
network of DICs in Swedish university hospitals [18]. The
DICs in Sweden offer evidence based drug information,
comparable to clinical consultations, to drug prescribing
health professionals [2, 18]. There are several DICs
established in other European countries with similar
working methods [18, 22].
We have found no published study on pediatric drug
treatment based on data from a DIC. However, three studies
concerning drug use in pregnancy or breast-feeding based
on data from DICs concluded that the DIC is an important
source of evidence based information [1, 9, 14].
The aim of this study was to analyse the characteristics
of Questions and Answers (Q&As) at a drug information
centre regarding drug related problems and off-label drug
treatment in children and also to analyse how often the DIC
could provide evaluated information concerning pediatric
drug use, in addition to the information available in the
Swedish catalogue of medical products.
Methods
Settings and subjects
A register of all Q&As handled by the DIC at the
Karolinska University Hospital, Huddinge, was used as
the information source for this study [2, 18]. When a
question is asked, a literature search is performed at the
DIC, the available information is evaluated and initially a
preliminary answer is given. The most frequent literature
sources used are medical databases, e.g. Medline, hand-
books, e.g. Martindale, and contacts with relevant author-
ities, e.g. medical products agency or the manufacturer.
After internal review and approval at a weekly staff meeting
a written answer with references is sent to the requester
[18]. All Q&As are continuously registered in a local
database, Dataease, which contains information concerning
question date, questioner, demographic data, drug and
medical history of the patient, and the drug related problem
in question (adverse reaction, interaction, kinetics, drug
choice and/or dosing, or drug formulation and/or adminis-
tration) and the answer delivered with literature references
[2, 18]. The Q&As of general interest are put into an
international database, Drugline, that is continually updated
by the DICs in Sweden, Odense Denmark and Åbo, Finland
[19].
All Q&As concerning children during a ten-year period,
from 1995 to 2004, were retrieved and systematically
analysed. Out of a total of 6,842 Q&As that were handled
at the DIC during this period, 300 (4.4%) concerned
children. The further analysis was restricted to Q&As
concerning children 15 years or younger. Fifty-one Q&As
(17%) were excluded from further analysis since they
concerned breast-feeding and/or pregnancy, patients
16 years or older, food, chemicals or doping or accidental
ingestion of drugs.
Classification
The questions were analysed and classified with respect to
the main drug related problem, drug/s and drug group/s,
pediatric labelling of the drug at the time the question was
raised, and age and sex of the patient (if known). Answers
relating to off-label treatment with drugs licensed in
Sweden were analysed with respect to their content of
evaluated literature information, adding to the information
given in the labelling of the drugs.
The off-label assessment was performed by using the
Swedish catalogue of medical products (FASS) from the
same year as the question [10]. A question was regarded as
off-label if any of the drugs was explicitly not recommen-
ded, or was given for an unproven indication, dose and/or
age-group in children. Questions concerning drugs for
which no information about the mode of pediatric use in
the patient was available, or for which safety and efficacy
studies had not been performed in a pediatric population,
were also regarded as off-label. All drugs that were not
listed in FASS were classified as unlicensed, e.g. drugs
prescribed on license bases or herbal remedies. The
licensed drugs were classified according to the Anatomical
Therapeutic Chemical classification system (ATC) up to the
5th level [29]. The register contains no references to patient
identity and therefore no ethical approval was needed for
the study.
Results
A total of 249 Q&As concerning children 15 years or
younger were identified, most of which originated from
hospital care (82%) and related to systemic drug exposure
(98%). Each question concerned an average of 1.5 drugs or
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herbal remedies. More than half of the questions concerned
use of drugs in an off-label (31%) or unlicensed (24%)
manner. The most common reason for off-label classifica-
tion of drugs was lack of pediatric labelling (53%),
followed by lack of safety and efficacy studies performed
in children (23%). As for the answers to questions
regarding off-label treatment, more than half (53%) were
classified as containing evaluated literature information
adding to the labelling of the drugs.
Table 1 gives the proportion of drug related problems
addressed for all the questions, and also for the groups of
questions concerning unlicensed or off-label drug use. The
last column gives the proportion of answers (to off-label
questions) containing information not included in the
labelling of the drugs, in relation to the type of drug related
problem.
Adverse drug reactions was the most common type of
drug related problem referred to in the questions (Table 1).
The most common types of adverse reactions were signs
and symptoms from the central nervous system (19%, e.g.
neuropathy or prolonged anesthesia), hematological reac-
tions (15%, e.g. thrombocytopenia or leucopenia) and skin
reactions (11%).
The majority of drugs (298 out of 372) included in the
questions were licensed in Sweden. The most common
therapeutic groups were antibacterial drugs for systemic
use, antiepileptics, antidepressants, vaccines, and neuro-
leptics and sedatives (Table 2).
Table 1 Proportion of drug related problems, off-label and/or unlicensed drug treatment in all questions (n=249), and proportion of evaluated
literature information, adding to the labelling of the drugs in off-label Q&A (n=78)
Drug related problem All (n=249 [100%])
[n (%)]
Unlicensed




(n=41 [16%]) [n (%)]
Adverse drug reactions 91 (37) 10 (17) 21 (27) 8 (20)
Pediatric drug choice and dosing 85 (34) 23 (39) 32 (41) 21 (51)
Drug interactions 31 (12) 10 (17) 14 (18) 6 (15)
Drug formulation and administration 25 (10) 14 (24) 5 (6) 1 (2)
Pediatric drug kinetics 17 (7) 2 (3) 6 (8) 5 (12)
Table 2 Proportion of drugs,
occurring five times or more in
questions, classified as off-la-
bel in different ATC groups
The total number of licensed
drugs was 298 among 249
enquiries. All data is not
shown.




Antibacterial drugs for systemic use J01 44 2
Antiepileptics N03 28 1
Neuroleptics and sedatives N05 23 14
Vaccines J07 18 0
Antidepressive agents N06A 16 13
Immunosuppressive agents L04 15 7
Drugs for obstructive airway diseases R03 14 0
Anesthetics N01 10 2
NSAID M01A 10 7
Corticosteroids for systemic use H02A 9 5
Antihistamines for systemic use R06A 9 1
Drugs for acid related disorders A02 7 2
Analgesics N02 8 4
Antidiarrheals, intestinal antiinflammatory/antiinfective agents A07 6 3
Antiprotozoals P01 6 1
Antithrombotic agents B01A 5 5
Antimycotics for systemic use J02 5 2
Antimycobacterials J04 5 2
Antivirals for systemic use J05 5 2
Pituitary, hypothalamic hormones and analogues H01 5 2
Diuretics C03 4 2
Beta blocking agents C07 4 3
Calcium channel blockers C08 4 3
Eur J Pediatr (2007) 166:527–532 529
Psychotropic drugs, immunosuppressive agents and anti-
inflammatory/antirheumatic agents were the drug groups
most frequently associatedwith off-label questions (Table 2).
Warfarin, risperidone, omeprazole, and different selective
serotonin reuptake inhibitors (all 3%) were the most
common drugs associated with off-label questions.
Questions concerning infants 0–1 years were most
common (n=41), with a proportion of off-label or unli-
censed treatment of 12%. However, this proportion was
highest for questions regarding adolescents (10–15 years)
(33% of 68 questions). Literature information, adding to the
information given in the labelling of drugs, was mainly found
for adolescents (Fig. 1). (Unfortunately, in one third of the
questions the age of the child was not specified or was not
applicable in questions of a more general character).
Discussion
This study, analysing pediatric Q&As at a DIC, confirms
that a large proportion of children, at least within hospital
care, are treated with drugs in a way that is not supported
by product labelling. In our data, we found that every
second question concerned off-label or unlicensed drug
treatment. Other hospital based studies have reported
frequencies of off-label drug treatment between 36 and
92% in pediatric patients [20]. This large variation in the
off-label frequency is partly explained by varying defini-
tions of the term off-label between countries and studies.
The most common reason for a licensed drug in our
questions to be classified as off-label was a lack of pediatric
labelling. Again, this is in accordance with earlier findings
[27]. However, the most important, and not previously
reported, finding in the present study is the amount of
information available through literature searching, that is
apparently relevant to pediatric drug treatment, but that is
not included in the product labelling of the drugs. For half of
all the questions regarded as off-label, additional pediatric
documentation was available from scientific publications
found mainly in Medline, but also from other drug therapy
literature sources, or through contact with the manufacturer.
One reason for the large proportion of off-label drug
treatment can thus be a lack of harmonisation between
existing documentation in the literature and drug licenses.
How can we make the best use of this information in
pediatric health care, to improve the efficacy and safety of
pediatric drug treatment? This finding does of course
support the importance of a health care facility like the
DIC, in providing condensed and evaluated literature
information, supporting the treatment of individual patients.
It has previously been shown that the DIC has a cost-saving
potential in preventing ADRs [15]. The present finding also
indicates the need, for example, of local or regional
pediatric therapeutic expert groups to regularly survey the
literature and distribute relevant new data and findings to
all pediatric prescribers. The Internet can be of good use for
this purpose, as exemplified by the Swedish webpage Janus
(http://www.janusinfo.se), which is a non-commercial web-
site, supported by the Stockholm county council, providing
drug information to support health care professionals in
their every day work.
In this context, it should be noted that a high proportion
of off-label drug treatment is not necessarily synonymous
with unsafe or incorrect pediatric treatment. It has been
shown that physicians are well aware of the lack of
pediatric labelling [8]. One reason for off-label drug use is
that pediatricians have clinical experience that supports off-
label drug use. Therefore, it is of great importance that such





















Off-label and/or unlicensed, with evaluated literature information
Off-label and/or unlicensed, without evaluated literature information
Within-label
Fig. 1 Number of Q&A classi-
fied as within label, off-label or
unlicensed with or without
answers resulted in evaluated
literature information adding to
the labelling of the drugs among
172 questions with known age
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The present study, in finding that adverse drug reactions
was the most common drug related problem, does also
emphasize that pediatric adverse drug reactions are of great
clinical relevance, in accordance with earlier studies [12,
25]. Adverse drug reactions were also often associated with
off-label drug treatment, as previously shown [13, 28].
Psychotropic drugs was the most common therapeutic
group of drugs in questions classified as off-label. This can
partly be explained by an increased use of these drugs, e.g.
selective serotonin reuptake inhibitors (SSRI), particularly
in adolescents [3–5, 17, 23]. Recently, the European
Agency for the Evaluation of Medicinal Products (EMEA)
approved the use of fluoxetine in the treatment of
depression in children eight years of age or older, who do
not respond to psychotherapy. However, only one question
in our material concerned fluoxetine.
We found some therapeutic drug groups that almost
totally lacked pediatric labelling, i.e. non-steroidal anti-
inflammatory drugs (NSAIDs) and antithrombotic drugs.
Especially for NSAIDs, more studies in the pediatric age
group is warranted, as these drugs are prescribed to a large
number of adult patients and can also be expected to have
an impact on pediatric drug treatment. As for antithrom-
botic agents, these drugs have little use in the pediatric
population. Nevertheless, antithrombotic drugs can be of
great importance for a concerned group of pediatric
patients.
Considering the lack of pediatric labelling for many
drugs, we regard the DIC as an important complement to
existing sources of drug information. The DICs also have
the potential to prevent drug related problems through their
pharmacological consultations. A future challenge is to
continually spread existing evidence based knowledge
regarding pediatric drug treatment to all physicians respon-
sible for treating pediatric patients. Foremost, there is still a
large need for increased research concerning pediatric drug
treatment.
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